erythromycin has been researched along with albuterol in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Amiama Pérez de Villarreal, C; Benito Fernández, J; Gaztelurrutia Abaitua, L; Gutiérrez Villamayor, C; Lazcoz Huarte, A; Mendia Gutiérrez, M; Montiano Jorge, JI; Pocheville Guruceta, I; Santiago Burruchaga, M | 1 |
| Goldstein, AO | 1 |
| Hueston, WJ | 2 |
| Littenberg, B; Smith, DS; Wheeler, M | 1 |
| Agarwalla, A; Agrawal, S; Jacob, M; Joshi, A; Sah, SP | 1 |
| Ekins-Daukes, S; Helms, PJ; McLay, JS; Taylor, MW | 1 |
1 review(s) available for erythromycin and albuterol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for erythromycin and albuterol
| Article | Year |
|---|---|
Acute bronchitis.
Topics: Acute Disease; Albuterol; Bronchitis; Double-Blind Method; Erythromycin; Humans; Research Design | 1992 |
A comparison of albuterol and erythromycin for the treatment of acute bronchitis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Bronchitis; Cough; Double-Blind Method; Erythromycin; Female; Humans; Male; Middle Aged; Prospective Studies; Smoking; Sputum; Suppuration; Time Factors | 1991 |
Albuterol delivered by metered-dose inhaler to treat acute bronchitis.
Topics: Acute Disease; Adult; Aerosols; Albuterol; Bronchitis; Combined Modality Therapy; Cough; Double-Blind Method; Erythromycin; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Smoking | 1994 |
A randomized controlled trial of oral albuterol in acute cough.
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Ambulatory Care; Antitussive Agents; Bronchitis; Cough; Dextromethorphan; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Erythromycin; Female; Humans; Male; Middle Aged; Prospective Studies | 1996 |
13 other study(ies) available for erythromycin and albuterol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
[Pertussis. Study of an epidemic].
Topics: Age Factors; Albuterol; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythromycin; Humans; Infant; Infant, Newborn; Spain; Whooping Cough | 1992 |
Palmar erythema nodosum.
Topics: Aged; Albuterol; Asthma; Drug Therapy, Combination; Erythema Nodosum; Erythromycin; Female; Hand Dermatoses; Humans; Prednisolone; Prognosis | 2000 |
Off-label prescribing to children: attitudes and experience of general practitioners.
Topics: Albuterol; Anti-Allergic Agents; Anti-Bacterial Agents; Attitude of Health Personnel; Bronchodilator Agents; Cetirizine; Child; Child, Preschool; Drug Administration Schedule; Drug Information Services; Drug Labeling; Drug Prescriptions; Erythromycin; Family Practice; Health Knowledge, Attitudes, Practice; Humans; Infant; Loratadine; Penicillin V; Prospective Studies; Scotland | 2005 |